Kay NE - Search Results

1

GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity.

Cox MJ, Manriquez Roman C, Tapper EE, Siegler EL, Chappell D, Durrant C, Ahmed O, Sinha S, Mwangi R, Scott NS, Hefazi M, Schick KJ, Horvei P, Ruff MW, Can I, Adada M, Bezerra E, Kankeu Fonkoua LA, Parikh SA, Kay NE, Sakemura R, Kenderian SS. Cox MJ, et al. Among authors: kay ne. Leukemia. 2022 Jun;36(6):1635-1645. doi: 10.1038/s41375-022-01572-7. Epub 2022 Apr 19. Leukemia. 2022. PMID: 35440691 Free PMC article.

2

B-chronic lymphocytic leukemia cells contain both endogenous kappa immunoglobulin mRNA and critical immunoglobulin gene activation transcription factors.

Zaknoen SL, Christian SL, Suen R, Van Ness B, Kay NE. Zaknoen SL, et al. Among authors: kay ne. Leukemia. 1992 Jul;6(7):675-9. Leukemia. 1992. PMID: 1625486

3

Malignant chronic lymphocytic leukemia B cells express interleukin 2 receptors but fail to respond to interleukin 2's proliferative signal.

Perri RT, Kay NE. Perri RT, et al. Among authors: kay ne. Leukemia. 1987 Feb;1(2):127-30. Leukemia. 1987. PMID: 3118104

4

B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules.

Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW, Hanson CA, Jelinek DF. Kay NE, et al. Leukemia. 2002 May;16(5):911-9. doi: 10.1038/sj.leu.2402467. Leukemia. 2002. PMID: 11986954

5

IL-4 biology: impact on normal and leukemic CLL B cells.

Kay NE, Pittner BT. Kay NE, et al. Leuk Lymphoma. 2003 Jun;44(6):897-903. doi: 10.1080/1042819031000068007. Leuk Lymphoma. 2003. PMID: 12854886 Review.

6

Reconstitution of innate immunity in B-chronic lymphocytic leukemia: time to reconsider the possibilities.

Lee YK, Kay NE. Lee YK, et al. Among authors: kay ne. Leukemia. 2003 Oct;17(10):1945-7. doi: 10.1038/sj.leu.2403082. Leukemia. 2003. PMID: 14513043 Review. No abstract available.

7

VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance.

Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. Lee YK, et al. Among authors: kay ne. Leukemia. 2005 Apr;19(4):513-23. doi: 10.1038/sj.leu.2403667. Leukemia. 2005. PMID: 15703780

8

ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype.

Nolz JC, Tschumper RC, Pittner BT, Darce JR, Kay NE, Jelinek DF. Nolz JC, et al. Among authors: kay ne. Leukemia. 2005 Jun;19(6):1018-24. doi: 10.1038/sj.leu.2403726. Leukemia. 2005. PMID: 15800671

9

CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation.

Pittner BT, Shanafelt TD, Kay NE, Jelinek DF. Pittner BT, et al. Among authors: kay ne. Leukemia. 2005 Dec;19(12):2264-72. doi: 10.1038/sj.leu.2403975. Leukemia. 2005. PMID: 16208411

10

Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

Zent CS, Wu W, Bowen DA, Hanson CA, Pettinger AM, Shanafelt TD, Kay NE, Leis JF, Call TG. Zent CS, et al. Among authors: kay ne. Leuk Lymphoma. 2013 Mar;54(3):476-82. doi: 10.3109/10428194.2012.717276. Epub 2012 Aug 22. Leuk Lymphoma. 2013. PMID: 22853816 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

460 results

Search Page